title: Altered microviscosity at brain membrane surface induces distinct and reversible inhibition of opioid receptor binding.
abstract: In synaptosomal membranes from rat and monkey brain cortex, the addition of petroselenic (18:1, cis-delta 6) acid, oleic (18:1, cis-delta 9) acid, and vaccenic (18:1, cis-delta 11) acid or their corresponding methyl esters at 0.5 mumol/mg of membrane protein caused a similar 7-10% decrease in the microviscosity of the membrane core, whereas at the membrane surface the microviscosity was reduced 5-7% by the fatty acids but only 1% by their methyl esters. Concomitantly, the fatty acids, but not the methyl esters, inhibited the specific binding of the tritiated mu-, delta-, and kappa-opioids Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAMGO), [D-Pen2,D-Pen5]enkephalin (DPDPE), and U69,593, respectively. As shown with oleic acid, the sensitivity of opioid receptor binding toward inhibition by fatty acids was in the order delta greater than mu much greater than kappa, whereby the binding of [3H]DPDPE was abolished, but significant inhibition of [3H]U69,593 binding, determined in membranes from monkey brain, required membrane modification with a twofold higher fatty acid concentration. Except for the unchanged KD of [3H]U69,593, the inhibition by oleic acid involved both the Bmax and affinity of opioid binding. Cholesteryl hemisuccinate (0.5-3 mumol/mg of protein), added to membranes previously modified by fatty acids, reversed the fluidization caused by the latter compounds and restored inhibited mu-, delta-, and kappa-opioid binding toward control values. In particular, the Bmax of [3H]-DPDPE binding completely recovered after being undetectable.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor 48109-0606.
authors.forename: D F
authors.initials: DF
authors.lastname: Lazar
authors.forename: F
authors.initials: F
authors.lastname: Medzihradsky
mesh_terms: D000818:Animals; D044482:Benzeneacetamides; D001921:Brain / Q000378:metabolism*; D002788:Cholesterol Esters / Q000494:pharmacology; D004952:Esters / Q000494:pharmacology; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology; D008560:Membrane Fluidity; D008566:Membranes / Q000378:metabolism; D009292:Narcotic Antagonists; D011759:Pyrrolidines / Q000378:metabolism; D013499:Surface Properties; D013574:Synaptosomes / Q000378:metabolism*; D014783:Viscosity
chemical_list: D044482:Benzeneacetamides; D002788:Cholesterol Esters; D004952:Esters; D005229:Fatty Acids, Monounsaturated; D009292:Narcotic Antagonists; D011759:Pyrrolidines; C045444:U 69593; C013440:cholesteryl succinate